Generic Name and Formulations:
Nitroglycerin 0.4mg/actuation; lingual aerosol spray.
Mist Pharmaceuticals, LLC
Indications for NITROMIST:
Acute attacks and prophylaxis of angina.
1–2 sprays at onset of attack, on or under tongue while sitting; may repeat every 5 minutes as needed; max 3 sprays/15 minutes. May use prophylactically 5–10 minutes before exertion. Do not inhale spray. Do not rinse mouth for 5–10 minutes after use.
Concomitant PDE5 inhibitors (eg, sildenafil, vardenafil, tadalafil), riociguat. Severe anemia. Increased intracranial pressure.
Volume depletion. Hypotension. Acute MI. CHF. Hypertrophic cardiomyopathy. Monitor for tolerance. Product is flammable. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Hypotension potentiated with PDE5 inhibitors, riociguat, antihypertensives, β-blockers, calcium channel blockers, alcohol. May be potentiated by aspirin. Nitroglycerin (IV) may antagonize t-PA, heparin (monitor APTT). Avoid concomitant ergotamine and related drugs. Do not use epinephrine to treat hypotension from nitrate overdose.
Headache (may be severe), flushing, rash, hypotension, syncope.
Bottles—4.1g (90 metered sprays), 8.5g (230 metered sprays)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline